Stockscreener 앱 받기
1.285
5.17%
-0.07
시간 외 거래:
1.32
0.035
+2.72%
Zentalis Pharmaceuticals Inc 주식(ZNTL)의 최신 뉴스
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages - Defense World
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Zentalis Strengthens Team with $194,600 in Equity Incentives - Stock Titan
Virtu Financial LLC Buys Shares of 24,973 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Leerink Partnrs Issues Pessimistic Outlook for ZNTL Earnings - Defense World
What is HC Wainwright’s Forecast for ZNTL Q1 Earnings? - Defense World
Leerink Partnrs Has Pessimistic Outlook of ZNTL Q1 Earnings - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Position Lifted by Charles Schwab Investment Management Inc. - Defense World
Wedbush Reiterates Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals: Hold Rating Amid Clinical Progress and Financial Uncertainty - TipRanks
Bank of New York Mellon Corp Sells 10,375 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Receives “Buy” Rating from HC Wainwright - Defense World
Zentalis Pharmaceuticals Reports Progress and Financials - TipRanks
Stifel maintains Buy on Zentalis stock with $9 target By Investing.com - Investing.com Canada
H.C. Wainwright sets $10 target for Zentalis shares, maintains Buy By Investing.com - Investing.com Canada
Zentalis Pharmaceuticals Inc Reports Annual EPS of -$2.33, Excee - GuruFocus
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates - GlobeNewswire
Zentalis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Zentalis Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - Marketscreener.com
Zentalis Breakthrough: 35% Response Rate in Ovarian Cancer Trial Wins FDA Fast Track - Stock Titan
Zentalis Pharmaceuticals to Present Multiple Posters at the - GlobeNewswire
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 - TradingView
Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
Zentalis pharmaceuticals director Luke Walker buys $24,966 in stock - MSN
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC Wainwright - The AM Reporter
H.C. Wainwright maintains $10 target on Zentalis stock By Investing.com - Investing.com Canada
Zentalis Highlights Promising Azenosertib Data at SGO 2025 - TipRanks
Zentalis Pharmaceuticals Presents Updated Clinical Data at - GlobeNewswire
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - MarketScreener
Zentalis Announces Updated Clinical Data From Part 1b Of DENALI Trial Of Azenosertib In PROC - Nasdaq
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - TradingView
Breakthrough: Zentalis Drug Achieves 35% Response Rate Against Hard-to-Treat Ovarian Cancer - Stock Titan
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Has Been Trading Down. What Are The Prospects For The Future? - stocksregister.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages - Defense World
ZNTL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Zentalis Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire
How Zentalis Is Attracting Talent: Inside Their Latest Employee Compensation Package - StockTitan
Zentalis Pharmaceuticals Announces Multiple Data - GlobeNewswire
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - The Manila Times
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Yahoo Finance
A company insider recently bought 20,000 shares of Zentalis Pharmaceuticals Inc [ZNTL]. Should You Buy? - Knox Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc.ZNTL - PR Newswire
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Can Zentalis' Novel Cancer Drug Pipeline Impress at Two Elite Healthcare Conferences? - StockTitan
Zentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on Tuesday - The AM Reporter
Zentalis stock price target cut to $10 by H.C. Wainwright - MSN
Zentalis pharmaceuticals officer sells $24,590 in stock - MSN
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently - Yahoo Finance
Savant Capital LLC Acquires New Shares in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis stock plunges to 52-week low, hits $2.16 - MSN
1.23%
1.63%
자본화:
|
볼륨(24시간):